We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $3.5B
1-Year Est. Return 1,165.83%
This Fund
S&P 500
This Quarter Est. Return
+18.76%
1 Year Est. Return
+1,165.83%
3 Year Est. Return
+3,168.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.18B
AUM Growth
+$221M
Cap. Flow
+$85.7M
Cap. Flow %
7.26%
Top 10 Hldgs %
58.4%
Holding
38
New
6
Increased
2
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
XNCR icon
Xencor
XNCR
+$45.6M
2
FULC icon
Fulcrum Therapeutics
FULC
+$38.9M
3
THRD
Third Harmonic Bio
THRD
+$29.9M
4
MBX
MBX Biosciences
MBX
+$14.9M
5
GPCR icon
Structure Therapeutics
GPCR
+$14.2M

Top Sells

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$41.8M
2
TARS icon
Tarsus Pharmaceuticals
TARS
+$9.12M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$8.65M
4
CCCC icon
C4 Therapeutics
CCCC
+$5.9M
5
SLN
Silence Therapeutics
SLN
+$4.87M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRDA icon
26
Entrada Therapeutics
TRDA
$236M
$9.35M 0.79%
584,955
– –
VTGN icon
27
VistaGen Therapeutics
VTGN
$9.45M
$8.06M 0.68%
2,676,580
– –
TARS icon
28
Tarsus Pharmaceuticals
TARS
$2.62B
$7.62M 0.65%
231,820
-324,497
-58% -$9.12M
EYPT icon
29
EyePoint Inc
EYPT
$1.04B
$7.37M 0.62%
922,335
– –
NKTR icon
30
Nektar Therapeutics
NKTR
$2.41B
$5.2M 0.44%
266,667
– –
JBIO
31
Jade Biosciences
JBIO
$1.21B
$4.68M 0.4%
64,023
– –
AVTX icon
32
Avalo Therapeutics
AVTX
$1.03B
$4.59M 0.39%
+483,000
New +$4.98M
KOD icon
33
Kodiak Sciences
KOD
$2.62B
$2.63M 0.22%
1,008,158
+108,159
+12% +$288K
ANTX icon
34
AN2 Therapeutics
ANTX
$178M
$1.66M 0.14%
1,555,118
– –
VTYX
35
DELISTED
Ventyx Biosciences
VTYX
$689K 0.06%
316,195
– –
CABA icon
36
Cabaletta Bio
CABA
$444M
$410K 0.03%
86,795
– –
CCCC icon
37
C4 Therapeutics
CCCC
$397M
– –
-1,276,574
Closed -$5.9M
MDGL icon
38
Madrigal Pharmaceuticals
MDGL
$12.7B
– –
-149,283
Closed -$41.8M
1
2

Similar funds

DILIC
Dai-ichi Life Insurance Company Tokyo, Japan $3.49B AUM 27.28% 1-Year Est. Return
KCM
Kedalion Capital Management London, United Kingdom $3.48B AUM 17.74% 1-Year Est. Return
ACM
Aquatic Capital Management Chicago, Illinois $3.48B AUM 24.9% 1-Year Est. Return
BCP
BDT Capital Partners Chicago, Illinois $3.51B AUM 31.02% 1-Year Est. Return
ACA
Anchor Capital Advisors Boston, Massachusetts $3.51B AUM 16.99% 1-Year Est. Return
MSC
MUFG Securities (Canada) New York $3.48B AUM 45.13% 1-Year Est. Return
TH
TCTC Holdings Dallas, Texas $3.51B AUM 30.71% 1-Year Est. Return
PMG
Private Management Group Irvine, California $3.47B AUM 13.39% 1-Year Est. Return

TCG Crossover Management's Q3 2024 Portfolio in Review

As of Q3 2024, TCG Crossover Management held 38 positions worth $1.18B, up 23% from $960M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

TCG Crossover Management deployed $85.7M of net new capital in Q3 2024, opening 6 new positions and adding to 2 existing holdings. Its largest new stake was Xencor: 2,427,138 shares worth $48.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Tarsus Pharmaceuticals, an estimated $9.12M trimmed.

  • TCG Crossover Management's largest Q3 2024 buy was Xencor: 2,427,138 shares worth $48.8M.
  • TCG Crossover Management added most to Structure Therapeutics in Q3 2024, an estimated $14.2M increase.
  • TCG Crossover Management's biggest Q3 2024 reduction was Tarsus Pharmaceuticals, cutting an estimated $9.12M.
  • TCG Crossover Management fully exited Madrigal Pharmaceuticals in Q3 2024, selling an estimated $41.8M.
  • TCG Crossover Management's ten largest holdings make up 58% of its $1.18B portfolio in Q3 2024.
  • TCG Crossover Management opened 6 new positions and closed 2 in Q3 2024.
  • TCG Crossover Management's portfolio value rose 23% quarter-over-quarter to $1.18B.

Based on TCG Crossover Management's 13F filing for Q3 2024, filed 14 Nov 2024.